Literature DB >> 2423177

Lack of correlation between clinical disease activity and erythrocyte sedimentation rate, acute phase proteins or protease inhibitors in ankylosing spondylitis.

N J Sheehan, B M Slavin, M P Donovan, J N Mount, J A Mathews.   

Abstract

Disease activity was assessed clinically and erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), orosomucoid, alpha 1-antitrypsin (alpha 1AT) and alpha 2-macroglobulin (alpha 2M) were measured in 65 patients with ankylosing spondylitis (AS). Positive correlations were found between ESR and the acute phase proteins (APP), CRP, orosomucoid and alpha 1AT, but none of these variables correlated with the clinical assessment of activity. No relationship was demonstrated between the protease inhibitor, alpha 2M and clinical activity, ESR or any of the APP. While the treatment of AS remains predominantly symptomatic, routine management of patients should continue to be founded on the clinical assessment of disease activity rather than on laboratory indices of inflammation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2423177     DOI: 10.1093/rheumatology/25.2.171

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  17 in total

1.  Stimulation of whole blood cultures in patients with ankylosing spondylitis by a mitogen derived from Mycoplasma arthritidis (MAS) and other mitogens.

Authors:  J M Brand; P Neustock; A Kruse; L Alvarez-Ossorio; A Schnabel; H Kirchner
Journal:  Rheumatol Int       Date:  1997       Impact factor: 2.631

2.  Disease activity assessment in ankylosing spondylitis in a Chinese cohort: BASDAI or ASDAS?

Authors:  Yuen Ling Elaine Au; Woon Sing Raymond Wong; Mo Yin Mok; Ho Yin Chung; Eric Chan; Chak Sing Lau
Journal:  Clin Rheumatol       Date:  2014-07-01       Impact factor: 2.980

3.  IgA-alpha 1 antitrypsin complexes in ankylosing spondylitis.

Authors:  G R Struthers; I V Lewin; D R Stanworth
Journal:  Ann Rheum Dis       Date:  1989-01       Impact factor: 19.103

4.  Serum aminoterminal type III procollagen peptide in inflammatory and degenerative rheumatic disorders.

Authors:  K Hørslev-Petersen; K D Bentsen; P Junker; F K Mathiesen; T M Hansen; I Lorenzen
Journal:  Clin Rheumatol       Date:  1988-03       Impact factor: 2.980

5.  Relationship between the severity of enthesitis and clinical and laboratory parameters in patients with ankylosing spondylitis.

Authors:  Taciser Kaya; Serpil Bal; Rezzan Gunaydin
Journal:  Rheumatol Int       Date:  2006-09-22       Impact factor: 2.631

6.  Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment.

Authors:  H G Taylor; E J Beswick; P T Dawes
Journal:  Clin Rheumatol       Date:  1991-03       Impact factor: 2.980

7.  Psychosocial factors and self-help in ankylosing spondylitis patients.

Authors:  J H Barlow; S J Macey; G Struthers
Journal:  Clin Rheumatol       Date:  1992-06       Impact factor: 2.980

8.  The clinical usefulness of ESR, CRP, and disease duration in ankylosing spondylitis: the product of these acute-phase reactants and disease duration is associated with patient's poor physical mobility.

Authors:  Chun-Hsiung Chen; Hung-An Chen; Hsien-Tzung Liao; Chin-Hsiu Liu; Chang-Youh Tsai; Chung-Tei Chou
Journal:  Rheumatol Int       Date:  2015-02-24       Impact factor: 2.631

9.  Assessment of therapeutic response in ankylosing spondylitis patients undergoing anti-tumour necrosis factor therapy by whole-body magnetic resonance imaging.

Authors:  Martina Karpitschka; Patrizia Godau-Kellner; Herbert Kellner; Annie Horng; Daniel Theisen; Christian Glaser; Bernhard Brandlhuber; Maximilian Reiser; Sabine Weckbach
Journal:  Eur Radiol       Date:  2013-03-15       Impact factor: 5.315

10.  Disease activity in longstanding ankylosing spondylitis: a correlation of clinical and magnetic resonance imaging findings.

Authors:  L Goh; P Suresh; A Gafoor; P Hughes; P Hickling
Journal:  Clin Rheumatol       Date:  2007-10-02       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.